halofuginone has been researched along with Lupus Erythematosus, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dou, H; Hou, Y; Li, X; Ni, J; Tu, X; Wang, S; Zhu, H | 1 |
| Bradley, J; Chaudhary, K; Koritzinsky, M; Liu, H; Madaio, MP; McGaha, TL; Ravishankar, B; Shinde, R; Xiao, W | 1 |
2 other study(ies) available for halofuginone and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Halofuginone ameliorates systemic lupus erythematosus by targeting Blk in myeloid-derived suppressor cells.
Topics: Animals; Lupus Erythematosus, Systemic; Mice; Myeloid-Derived Suppressor Cells; Piperidines; Quinazolinones | 2023 |
The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity.
Topics: Amino Acids; Animals; Apoptosis; Autoimmunity; Cells, Cultured; Cytokines; Disease Models, Animal; Gene Expression Regulation; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Lupus Erythematosus, Systemic; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Cells; Piperidines; Protein Serine-Threonine Kinases; Quinazolinones; Signal Transduction | 2015 |